Skip to content

Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy

Effects of Intensive Insulin Therapy on Mortality, Morbidity and Long Term Neurologic Outcome in Neurosurgical Intensive Care Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00505505
Enrollment
800
Registered
2007-07-23
Start date
2002-01-31
Completion date
Unknown
Last updated
2008-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Hemorrhage, Subarachnoid Hemorrhage, Traumatic Brain Injury

Keywords

Neurointensive care, Intensive insulin infusion, Hypoglycemia, Postoperative Mortality, Postoperative Morbidity, Neurologic outcome

Brief summary

Strict glycemic control improves mortality and morbidity of patients admitted to the postoperative intensive care unit (ICU). The investigators would like to know if this therapy could improve the long term neurologic and cognitive outcomes of patients treated for acute subarachnoid hemorrhage with either a surgical or intravascular approach.

Detailed description

Intensive Insulin Therapy and Strict Glycemic Control (80-120 mg/dL) Versus Standard Insulin Therapy in Neurosurgical Intensive Care Patients (Subarachnoid Hemorrhage, Traumatic Brain Injury, Intracranial Expanding Lesion): Safety, and Efficacy (Mortality, Morbidity, Long Term Neurologic Outcome).

Interventions

DRUGInsulin (Actrapid)

50 UI Actrapid diluted in 50 ml of saline

Sponsors

University of Roma La Sapienza
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Subarachnoid hemorrhage * Traumatic brain injury * Intracranial hemorrhage

Design outcomes

Primary

MeasureTime frame
Episodes of hypoglycemia

Secondary

MeasureTime frame
Infection rateduring the study
Vasospasm rateduring the study
Mortality6 months follow up
Neurologic status6 months follow up

Countries

Italy

Contacts

Primary ContactFederico Bilotta, MD, PhD
bilotta@tiscali.it39 339 33 708 22
Backup ContactVincenzo Cuzzone

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026